Abstract
Background and objective Dementia prevention has been recognized as a top priority by public health authorities due to the lack of disease modifying treatments. In this regard, digital dementia-preventive lifestyle services (DDLS) emerge as potentially pivotal services, aiming to address modifiable risk factors on a large scale. This study aims to identify the top-funded companies offering DDLS globally and evaluate their clinical evidence to gain insights into the current state of the global service landscape.
Methods A systematic screening of two financial databases (Pitchbook and Crunchbase) was conducted. Corresponding published clinical evidence was collected through a systematic literature review and analyzed regarding study purpose, results, quality of results, and level of clinical evidence.
Findings The ten top-funded companies offering DDLS received a total funding of EUR 128.52 million, of which three companies collected more than 75%. Clinical evidence was limited due to only nine eligible publications, small clinical subject groups, the absence of longitudinal study designs, and no direct evidence of dementia prevention.
Conclusion The study highlights the need for a more rigorous evaluation of DDLS effectiveness in today’s market. It serves as a starting point for further research in digital dementia prevention.
Competing Interest Statement
RV, PH, TK, and MN are affiliated with the Centre for Digital Health Interventions (CDHI), a joint initiative of the Institute for Implementation Science in Health Care, University of Zurich, the Department of Management, Technology, and Economics at the ETH Zurich, and the institute of Technology Management and School of Medicine at the University of St. Gallen. CDHI is funded in part by CSS, a Swiss health insurer, Mavie Next, an Austrian healthcare provider and MTIP, a Swiss investor company. TK is also a co-founder of Pathmate Technologies, a university spin-off company that creates and delivers digital clinical pathways. However, neither CSS nor Pathmate Technologies, Mavie Next, or MTIP was involved in this research. All other authors declare no conflict of interest.
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present work are contained in the manuscript
